



HELLENIC REPUBLIC  
CAPITAL MARKET COMMISSION

---

**PRESS RELEASE**

Athens, November 24, 2021

The Board of Directors of the Hellenic Capital Market Commission at its 971<sup>st</sup>/24.11.2022 meeting approved the prospectus of the company "LAVIPHARM S.A." for the public offering up to 170,588,235 new, common, registered, with voting rights shares, to raise funds up to € 57,999,999, through cash payment, and preemptive rights in favour of the existing shareholders. The new shares of LAVIPHARM S.A. will be admitted to trading on the regulated market of the Athens Exchange.